University of California, Los Angeles About Us   |   Diversity and Inclusion  |   Contact Us   |   Campus Directory   |   Giving   |   Maps/Directions
RESEARCH

Dennis Slamon, M.D., Ph.D.

Contact Information:

Work Phone Number:

(310) 825-5193
(888) ONC-UCLA

Work Address:

700 Tiverton Ave
11-934 Factor
CAMPUS - 167817
Los Angeles, CA 90095
UNITED STATES

Work Email Address:

dslamon@mednet.ucla.edu

Chair, Hematology/Oncology

Chief, Hematology-Oncology

Oncology Treatment Center at UCLA

Vice-Chair, Research, and

Professor, Medicine

Member, Internal Advisory Board

JCCC Signal Transduction and Therapeutics Program Area

CTSI

Dumont-UCLA Liver Cancer Center


A Short Biography:

Dennis J. Slamon, M.D., Ph.D., serves as director of Clinical/Translational Research, and as director of the Revlon/UCLA Women's Cancer Research Program at JCCC. He is a professor of medicine, chief of the Division of Hematology/Oncology and executive vice chair for research for UCLA's Department of Medicine. Slamon also serves as director of the medical advisory board for the National Colorectal Cancer Research Alliance, a fund-raising organization that promotes advances in colorectal cancer. For 12 years, Dr. Slamon and his colleagues conducted the laboratory and clinical research that led to the development of the new breast cancer drug Herceptin, which targets a specific genetic alteration found in about 25 percent of breast cancer patients. To acknowledge Slamon's accomplishments, President Clinton appointed Slamon to the three-member President's Cancer Panel in June 2000. A 1975 honors graduate of the University of Chicago's Pritzker School of Medicine, Slamon earned his Ph.D. in cell biology that same year. He completed his internship and residency at the University of Chicago Hospitals and Clinics, becoming chief resident in 1978. One year later, he became a fellow in the Division of Hematology/Oncology at UCLA.

Awards and Honors:

University of Chicago Hospitals
University of Chicago Hospitals
UCLA School of Medicine

Detailed Biography:

Dennis J. Slamon, M.D., Ph.D., serves as director of Clinical/Translational Research, and as director of the Revlon/UCLA Women's Cancer Research Program at JCCC. He is a professor of medicine, chief of the Division of Hematology/Oncology and executive vice chair for research for UCLA's Department of Medicine. Slamon also serves as director of the medical advisory board for the National Colorectal Cancer Research Alliance, a fund-raising organization that promotes advances in colorectal cancer.

For 12 years, Slamon and his colleagues conducted the laboratory and clinical research that led to the development of the new breast cancer drug Herceptin, which targets a specific genetic alteration found in about 25 percent of breast cancer patients. To acknowledge Slamon's accomplishments, President Clinton appointed Slamon to the three-member President's Cancer Panel in June 2000.

Slamon has won nearly two dozen national research awards honoring his scientific endeavors. In 2000, Slamon was awarded the Translational Medicine Award by the USCD-Salk Institute as well as the Bristol-Myers Squibb Oncology Millennium Award for significant achievement and leadership in breast cancer research. In 2001, Slamon was awarded the Wadsworth Center's Brown-Hazen Award for Excellence in the Basic Sciences, and in 2002, he received the Jeffrey A. Gottlieb Memorial Award from the M.D. Anderson Cancer Center in Texas. In 2003, Slamon received the Dorothy P. Landon-AACR Prize for Translational Cancer Research, an international award given by the Kirk A. and Dorothy P. Landon Foundation and the American Association for Cancer Research. In 2004, the American Cancer Society presented Slamon with the Medal of Honor, the top award bestowed by the organization. In 2005, Kent State University in Ohio gave Slamon the Fifth Aultman Cancer Center Award and he also received the Distinguished Service Award from the Medical and Biological Sciences Alumni Association at the University of Chicago. That same year, he received the William McGuire Memorial Award at the San Antonio Breast Cancer Symposium.

In 2006, Slamon was honored with the American Society of Clinical Oncology's David A. Karnofsky Memorial Award and Lecture. Also in 2006, Slamon received the 18th Annual Donald Ware Waddell Award from Arizona Cancer Center; the European Institute of Oncology Breast Cancer Award; the 2nd Umberto Veronesi Award for the Future Fight Against Breast Cancer and the Lister Award for Translational Medicine from the University of Glasgow, Scotland. In 2007, Slamon received the 19th annual Warren Alpert Foundation Scientific Prize, awarded by Harvard Medical School. Also in 2007, he received the Friends of the National Library of Medicine Distinguished Medical Service Award and the Gairdner International Award, one of the most prestigious awards in biomedical science.

In 2008, Slamon received the Daniel Nathans Memorial Award from the Van Andel Research Institute and in 2009, he was awarded the Medical Science Award by the UCLA Medical Alumni and Aesculapians. Slamon has also received the Milken Family Medical Foundation Award in Cancer Research, the Upjohn Award in Internal Medicine and the Outstanding Young Investigator Award.

A 1975 honors graduate of the University of Chicago's Pritzker School of Medicine, Slamon earned his Ph.D. in cell biology that same year. He completed his internship and residency at the University of Chicago Hospitals and Clinics, becoming chief resident in 1978. One year later, he became a fellow in the Division of Hematology/Oncology at UCLA.

Selected Publications:

Oh JJ, Fishbein MC, Boctor B, Jimenez CA, Lopez R, Slamon DJ Evaluation of H37, a candidate 3p21.3 tumor suppressor gene, as a therapeutic and diagnostic marker in lung cancer. Chest. 2004; 125(5 Suppl): 102S-3S.
Slamon DJ The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors.. The oncologist. . 2004; 9 Suppl 3: 1-3.
Finn RS, Slamon DJ Monoclonal antibody therapy for breast cancer: herceptin. Cancer Chemother Biol Response Modif. 2003; 21: 223-33.
Kalous Ondrej, Conklin Dylan, Desai Amrita J, O'Brien Neil A, Ginther Charles, Anderson Lee, Cohen David J, Britten Carolyn D, Taylor Ian, Christensen James G, Slamon Dennis J, Finn Richard S Dacomitinib (PF-00299804), a irreversible pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.. Molecular cancer therapeutics. 2012; .
Britten Carolyn D, Gomes Antoinette S, Wainberg Zev A, Elashoff David, Amado Rafael, Xin Yan, Busuttil Ronald W, Slamon Dennis J, Finn Richard S Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study.. BMC cancer. 2012; 12(4): 16.
Zhu Min, Saxton Romaine E, Ramos Lillian, Chang David D, Karlan Beth Y, Gasson Judith C, Slamon Dennis J Neutralizing monoclonal antibody to periostin inhibits ovarian tumor growth and metastasis.. Molecular cancer therapeutics. 2011; 10(8): 1500-8.
Bryant JA, Finn RS, Slamon DJ, Cloughesy TF, Charles AC EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells.. Cancer biology & therapy. . 2004; 3(12): 1243-9.
Konecny GE, Thomssen C, Luck HJ, Untch M, Wang H, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Steinfeld D, Mobus V, von Minckwitz G, Dandekar S, Ramos L, Pauletti G, Pegram MD, Janicke F, Slamon DJ Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst. 2004; 96(15): 1141-51.
Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, Peck J, Ruddon RW, Sigman CC, Slamon DJ Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.. Clinical cancer research : an official journal of the American Association for Cancer Research. . 2004; 10(11): 3885-96.
Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.. Journal of the National Cancer Institute. . 2004; 96(10): 739-49.
Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, Quan E, Crown J, Toppmeyer D, Smylie M, Riva A, Blitz S, Press MF, Reese D, Lindsay MA, Slamon DJ Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.. Journal of the National Cancer Institute. . 2004; 96(10): 759-69.
Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, Murphy M, Stewart SJ Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. . 2004; 22(6): 1063-70.
Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ, Pegram MD Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients.. Clinical cancer research : an official journal of the American Association for Cancer Research. . 2004; 10(5): 1706-16.
Konecny GE, Wilson CA, Slamon DJ Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention?. Journal of the National Cancer Institute. . 2003; 95(24): 1813-5.
Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.. Journal of the National Cancer Institute. . 2003; 95(2): 142-53.
Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, Danino M, Karlan BY, Slamon DJ Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells.. Cancer research. . 2003; 63(1): 196-206.
UCLA    |    Terms & Conditions    |    Disability Resources    |    UC Regents